BNXTF (BioNxt Solutions) Beneish M-Score: 0.00 (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BNXTF BioNxt Solutions Inc BNXTF
24 GF Score
Price $0.23
! 4 Warning Signs
View Full Analysis

What is BioNxt Solutions Beneish M-Score?

BioNxt Solutions BNXTF +2.87% 24 Beneish M-Score is 0.00 as of Aug. 14, 2026. GuruFocus rates BNXTF with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 913 Drug Manufacturers companies, BioNxt Solutions ranks worse than 109528.92% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for BioNxt Solutions's Beneish M-Score or its related term are showing as below:

During the past 8 years, the highest Beneish M-Score of BioNxt Solutions was 235.56. The lowest was -25.64. And the median was -4.83.

BioNxt Solutions Beneish M-Score Historical Data

* Premium members only.

The historical data trend for BioNxt Solutions's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNxt Solutions Beneish M-Score Chart

BioNxt Solutions Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 140.49 -5.21 -11.80 0.00 0.00

BioNxt Solutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.83 0.00 0.00 0.00 0.00

BNXTF vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioNxt Solutions's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNxt Solutions Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioNxt Solutions's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioNxt Solutions's Beneish M-Score falls into.


BNXTF
24GF Score
BioNxt Solutions Inc BNXTF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioNxt Solutions Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BioNxt Solutions for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $0.02 Mil.
Revenue was 0 + -0.008 + 0.008 + 0 = $0.00 Mil.
Gross Profit was 0 + -0.008 + 0.008 + 0 = $0.00 Mil.
Total Current Assets was $0.06 Mil.
Total Assets was $0.24 Mil.
Property, Plant and Equipment(Net PPE) was $0.15 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.01 Mil.
Selling, General, & Admin. Expense(SGA) was $4.33 Mil.
Total Current Liabilities was $4.80 Mil.
Long-Term Debt & Capital Lease Obligation was $0.78 Mil.
Net Income was -3.095 + -1.556 + -1.159 + -0.951 = $-6.76 Mil.
Non Operating Income was -0.785 + -0.102 + 0.051 + 0.157 = $-0.68 Mil.
Cash Flow from Operations was -0.429 + -0.794 + -1.465 + -0.555 = $-3.24 Mil.
 Total Receivables was $0.11 Mil.
Revenue was 0 + 0.004 + 0.013 + 0.001 = $0.02 Mil.
Gross Profit was 0 + 0.004 + 0.013 + 0.001 = $0.02 Mil.
Total Current Assets was $0.47 Mil.
Total Assets was $0.71 Mil.
Property, Plant and Equipment(Net PPE) was $0.24 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.05 Mil.
Selling, General, & Admin. Expense(SGA) was $2.58 Mil.
Total Current Liabilities was $3.08 Mil.
Long-Term Debt & Capital Lease Obligation was $2.90 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.024 / 0) / (0.108 / 0.018)
= / 6
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.018 / 0.018) / (0 / 0)
=1 /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.055 + 0.152) / 0.243) / (1 - (0.472 + 0.236) / 0.708)
=0.148148 / 0
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0.018
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.046 / (0.046 + 0.236)) / (0.013 / (0.013 + 0.152))
=0.163121 / 0.078788
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(4.334 / 0) / (2.575 / 0.018)
= / 143.055556
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.775 + 4.801) / 0.243) / ((2.895 + 3.08) / 0.708)
=22.946502 / 8.439266
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-6.761 - -0.679 - -3.243) / 0.243
=-11.683128

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
BioNxt Solutions (BNXTF) has a Beneish M-Score of 0.00 as of Aug. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on BioNxt Solutions and its competitors. According to the industry distribution chart, BioNxt Solutions ranks #999999 out of 913 companies in the Drug Manufacturers industry.
Is BioNxt Solutions' Beneish M-Score too high?
BioNxt Solutions' current Beneish M-Score is 0.00. Based on the distribution chart, BioNxt Solutions ranks #999999 out of 913 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioNxt Solutions has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does BioNxt Solutions' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioNxt Solutions ranks #999999 out of 913 companies for Beneish M-Score. This places BioNxt Solutions in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on BioNxt Solutions and its competitors. BioNxt Solutions's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNxt Solutions stock overvalued right now?
BioNxt Solutions (BNXTF) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. BioNxt Solutions' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For BioNxt Solutions (BNXTF), the current Beneish M-Score is 0.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioNxt Solutions Business Description

Other Exchanges BXT:GermanyBNXT:Canada
Address 1928 Linden Road, Vancouver, BC, CAN, V6M 1E7
BioNxt Solutions Inc is is a bioscience innovator focused on next-generation drug delivery systems. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, focused on European markets. The company is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes. Its pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, BNT24004. Its geographic areas are Austria, Germany, Switzerland regions.
24GF Score

Get the complete analysis for BNXTF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price